Next-generation sequencing, proteomics analysis, and circulating tumor DNA demonstrate how precision medicine advances ...
The next-generation sequencing market valued at US$ 13.92 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, ...
For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...
The webinar series titled "The Basics of Next Generation Sequencing and its Application in Precision Oncology" aims to provide a comprehensive understanding of the fundamentals and practical ...
Genetic changes have the ability to alter crop characteristics, and some crop breeding techniques take advantage of this. Conventionally, genetic engineering has relied on natural or artificial ...
Results of a study led by the Vall d'Hebron Institute of Oncology (VHIO) support the feasibility of using RAD51 testing to ...
Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...
A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...
Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback